<?xml version='1.0' encoding='utf-8'?>
<document id="23640987"><sentence text="Integrated approach of in vivo and in vitro evaluation of the involvement of hepatic uptake organic anion transporters in the drug disposition in rats using rifampicin as an inhibitor."><entity charOffset="157-167" id="DDI-PubMed.23640987.s1.e0" text="rifampicin" /></sentence><sentence text="Cumulative studies describe the importance of drug transporters as one of the key determinants of pharmacokinetics that necessitate investigation and assessment of the involvement of drug transporters in drug discovery and development" /><sentence text=" The present study investigated an integrated in vivo and in vitro approach to determine the involvement of organic anion transporting polypeptides (Oatps) in the disposition of drugs in rats using rifampicin as an inhibitor"><entity charOffset="198-208" id="DDI-PubMed.23640987.s3.e0" text="rifampicin" /></sentence><sentence text=" When bromosulfophthalein (BSP) and HMG-CoA reductase inhibitors (statins), which were used as model substrates for Oatps, were administered intravenously (3 and 1 mg/kg, respectively) to rats pretreated with rifampicin orally (30 mg/kg), the total plasma clearance of BSP and statins was attenuated compared with that in control rats, suggesting the involvement of Oatps in the disposition of these drugs in vivo"><entity charOffset="6-25" id="DDI-PubMed.23640987.s4.e0" text="bromosulfophthalein" /><entity charOffset="27-30" id="DDI-PubMed.23640987.s4.e1" text="BSP" /><entity charOffset="209-219" id="DDI-PubMed.23640987.s4.e2" text="rifampicin" /><entity charOffset="269-278" id="DDI-PubMed.23640987.s4.e3" text="BSP" /><pair ddi="false" e1="DDI-PubMed.23640987.s4.e0" e2="DDI-PubMed.23640987.s4.e0" /><pair ddi="false" e1="DDI-PubMed.23640987.s4.e0" e2="DDI-PubMed.23640987.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23640987.s4.e0" e2="DDI-PubMed.23640987.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23640987.s4.e0" e2="DDI-PubMed.23640987.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23640987.s4.e1" e2="DDI-PubMed.23640987.s4.e1" /><pair ddi="false" e1="DDI-PubMed.23640987.s4.e1" e2="DDI-PubMed.23640987.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23640987.s4.e1" e2="DDI-PubMed.23640987.s4.e3" /><pair ddi="false" e1="DDI-PubMed.23640987.s4.e2" e2="DDI-PubMed.23640987.s4.e2" /><pair ddi="false" e1="DDI-PubMed.23640987.s4.e2" e2="DDI-PubMed.23640987.s4.e3" /></sentence><sentence text=" On the other hand, the pharmacokinetics of midazolam, used as a model substrate of cytochrome P450 3a (Cyp3a), was unchanged between control rats and rifampicin-pretreated rats"><entity charOffset="44-53" id="DDI-PubMed.23640987.s5.e0" text="midazolam" /><entity charOffset="151-161" id="DDI-PubMed.23640987.s5.e1" text="rifampicin" /><pair ddi="false" e1="DDI-PubMed.23640987.s5.e0" e2="DDI-PubMed.23640987.s5.e0" /><pair ddi="false" e1="DDI-PubMed.23640987.s5.e0" e2="DDI-PubMed.23640987.s5.e1" /></sentence><sentence text=" The involvement of Oatps in the disposition of statins observed in vivo was further clarified by employing an in vitro hepatic uptake study and media-loss assay in the presence or absence of 100 Î¼M rifampicin"><entity charOffset="199-209" id="DDI-PubMed.23640987.s6.e0" text="rifampicin" /></sentence><sentence text=" Hepatic intrinsic clearance was reduced in the presence of rifampicin in both the media-loss assay and hepatocyte uptake study"><entity charOffset="60-70" id="DDI-PubMed.23640987.s7.e0" text="rifampicin" /></sentence><sentence text=" The present study suggests in vivo investigations in rats using rifampicin together with in vitro investigations with a media-loss assay and/or uptake assay using rat hepatocytes can help determine whether a clinical drug-drug interaction study is necessary in drug development"><entity charOffset="65-75" id="DDI-PubMed.23640987.s8.e0" text="rifampicin" /></sentence><sentence text="" /></document>